1

SARS-CoV-2 Fusion Peptide-Directed Antibodies Are Elicited by Natural Infection and

Can Mediate Broad Sarbecovirus Neutralization

Alex L. Roederer[1], Chia Jung Li[1], Eunice Lim[1], Yi Cao[1], David H. Canaday[2,3], Stefan

Gravenstein[4,5,6], Alejandro B. Balazs[1,*]

[1]Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA

[2]Case Western Reserve University School of Medicine, Cleveland, OH

[3]Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center,

Cleveland, Ohio

[4]Center of Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island

[5]Division of Geriatrics and Palliative Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.

[6]Brown University School of Public Health Center for Gerontology and Healthcare Research, Providence, Rhode Island

*Lead Contact, correspondence: abalazs@mgh.harvard.edu

SUMMARY

Studies have demonstrated that repeated mRNA vaccination enhances the breadth of
neutralization against diverse SARS-CoV-2 variants. However, the development of antibodies
capable of neutralizing across the Coronavirinae subfamily is poorly understood. In this study,
we analyze serum samples to determine their neutralization breadth and potency and identify
their antigenic targets. Using a cohort of older individuals and healthcare workers, we track
correlates of broad neutralizing responses, including fusion peptide (FP) antibody elicitation. We
find that although broadly neutralizing responses are often a result of RBD-specific antibodies, a
rare subset of donors produce FP-specific broadly neutralizing responses. Interestingly, FP-
specific antibodies are not observed in COVID-naive individuals irrespective of vaccination
regimen, but rather, they occur following natural infection or vaccine breakthrough. This study
highlights which epitope targets underpin broadly neutralizing antibody responses to
coronaviruses and suggests that existing vaccines are insufficient to promote the elicitation of
FP-directed broadly neutralizing coronavirus antibodies.

KEYWORDS: COVID-19; SARS-COV-2; broad neutralization; fusion peptide; stem helix;
neutralizing antibodies

Introduction

SARS-CoV-2 first appeared at the end of 2019 in Wuhan, China and quickly spread across the world, with an estimated 778 million documented infections leading to over 7 million documented deaths[1], though this is likely to be a gross underestimate[2]. The global impact of this virus resulted in the development of multiple monoclonal neutralizing antibodies and vaccines to limit disease severity. The spike protein is the predominant target of neutralizing antibodies against SARS-CoV-2. The spike is composed of two subunits, the S1 which contains the receptor binding domain (RBD) and the N-Terminal Domain (NTD), and the S2, which contains the highly conserved Fusion Peptide (FP), and the fusion machinery which contains the conserved Stem Helix (SH). The RBD is the predominant target of neutralizing antibodies given its role in binding to the ACE2 receptor on host cells[3]. In the second year of the pandemic, numerous monoclonal antibodies targeting the RBD were approved for treatment but have since been rendered ineffective due to escape by SARS-CoV-2 variants[4–6]. This escape highlights the urgent need for preventive therapies including vaccines that will more effectively target future variants.

COVID-19 vaccination has been critical for prevention of severe disease from SARS-CoV-2 worldwide. The first generation of COVID vaccines[7–10] were based on the Wuhan strain of SARS-CoV-2 spike protein, containing 2 proline-stabilizing mutations that were previously used to stabilize other related spike proteins[11]. Numerous SARS-CoV-2 variants have arisen over the last four years, which display immune evasion and changes in viral infectivity[12–18]. The mRNA vaccine has been reformulated multiple times, first to a bivalent composition of Wuhan and BA.5 variant spike sequences[19–22], and then to a monovalent XBB.1.5 spike sequence[23–26], and more recently to a monovalent KP.2 spike sequence[27].

Despite these reformulations being highly effective against individual variants they were directed toward, the virus continued to mutate with the JN.1 and KP.2 variants escaping XBB.1.5 boosted sera effectively[18,28,29]. At their peak, JN.1 and offshoot variants including KP.2 made up over 96% of all sequences being submitted to the GISAID database[30]. A majority of mutations in variants have occurred in the RBD region with JN.1 and KP.2 having 28-29 of their 58-61 mutations in the RBD, driving the escape of the humoral immune response[28–32].

Despite the plethora of vaccines, the virus has continued to evade humoral immune responses due to the immunodominance of RBD-directed antibodies and the selective pressure on this region. Notably, the FDA met in the summer of 2024 to formulate a vaccine for 2025[33], suggesting that COVID vaccines will continue to be updated annually, much like those for Influenza, potentially costing billions each year[34,35]. Understanding the nature of rare broadly

neutralizing responses to SARS-CoV-2 in patients is crucial for the development of next-
generation vaccines that can uniformly elicit broadly neutralizing coronavirus antibodies.

Ideally, coronavirus broadly neutralizing antibodies would neutralize all existing SARS-
CoV-2 variants and be cross-protective against strains likely to emerge in the future. Therefore,
future vaccines could target highly conserved regions within the spike protein. There are several
highly conserved regions within the RBD among SARS-CoV-2 variants that can be targeted by
neutralizing antibodies[36,37]. However, it has been theorized that the mutational landscape in the
RBD is incredibly vast[38], and strong immune pressure has consistently selected for the RBD
escape mutations found in existing variants. The SH is conserved among betacoronaviruses
while the FP is conserved among all coronaviruses. Multiple groups have identified broadly
cross-reactive and neutralizing antibodies that target these less common epitopes[39–46]. Given its
conservation across even distantly related coronaviruses, the FP represents an ideal target
antigen for vaccine design, however it is unclear how these neutralizing antibodies to FP are
elicited.

To understand the development of broadly neutralizing antibody responses, we
characterized donor sera with widely different neutralizing potency and breadth for binding to
conserved antigenic sites within the spike protein. Interestingly, we find that the most potent
neutralizers have the highest RBD, SH and FP titers despite similar spike IgG ELISA titers as
less potent donors. Furthermore, among broad neutralizers we find that RBD and FP specific
antibodies correlate with neutralizing titer to SARS-CoV-2. To further understand the make-up of
a broadly neutralizing antibody response, we selectively depleted antibodies to the RBD, FP
and SH. We find that while RBD antibodies are predominantly responsible for broad
neutralization, as others have seen[41,47–49], there exist rare donors with neutralizing FP
antibodies that contribute significantly to breadth, however, FP antibody development is limited
in most donors. Importantly, we find that FP antibodies develop following natural infection, and
that additional vaccination leads to a decline in FP-specific antibody titers. Taken together,
these results highlight the shortcomings of existing vaccination regimens to elicit highly cross-
reactive, broadly neutralizing antibodies.

RESULTS

Broad neutralizers have extensive breadth across related Betacoronaviruses.

To investigate the breadth of neutralization, a cohort of 382 donor samples collected at different timepoints after vaccination were evaluated for WT, BA.1 or BA.5 spike pseudovirus neutralization (**Figure S1A**). Notably, some samples exhibited potent neutralizing activity against all three viruses, exceeding the limit of detection of our assay. Samples were binned into distinct groups based on neutralizing titers across the three variants (**Figure 1A**). Samples with $pNT_{50} > 2000$ against WT and > 1500 against both BA.1 and BA.5 were classified as *Broad-Potent*. Samples with at least one but not all pNT_{50} values exceeding these thresholds were classified as *Narrow-Potent*. Samples with $pNT_{50} < 300$ against WT and < 100 against BA.1 and BA.5 were classified as *Weak*, and all remaining samples were classified as *Moderate*. To determine whether these broadly neutralizing responses could extend to other human infecting coronaviruses, a subset from each group of neutralizers were further tested against multiple related betacoronaviruses and two common cold alphacoronaviruses (**Figure 1B**). We developed high throughput neutralization assays for pseudoviruses representing these diverse viruses. Given that 229E and MERS use human Aminopeptidase (hANPEP)[50,51] and dipeptidyl peptidase-4 (hDPP4)[52,53] as cell receptors, stable cell lines expressing these cell-surface proteins were developed and confirmed to express their respective receptors by flow cytometry (**Figure S1B, C**). Each cell line was susceptible to their respective pseudoviruses and neutralization assays with previously described neutralizing antibodies resulted in IC_{50} values that were similar to those previously reported[43,45] (**Figure S1D**). The most potent and broad neutralizers exhibited activity against SARS-CoV-2 variants, SARS-CoV, and WIV1, but this high level of potency did not extend to other alphacoronaviruses including NL63, 229E or the betacoronavirus MERS.

Broad-potent neutralizers were re-tested at a higher dilution to allow for more accurate assessment of maximum neutralizing titers, which enabled further subdivision into *broad-extra-potent* and *broad-potent* based on an average of pNT50 values against SARS-CoV-2 WT and variants, SARS-CoV, and WIV1 (**Figure 1C**). While *broad-potent* sera exhibited extensive activity against SARS-CoV-2 WT, BA.1 and BA.5 variants, it lacked substantial neutralizing titer against related Betacornaviruses SARS-CoV and WIV1 as compared to *broad-extra-potent* sera. Average pNT_{50} values were re-calculated using values obtained from the extended dilution range assays. *Broad-extra-potent* neutralizers had a significantly higher average pNT_{50} of 16,191 while *broad-potent* had an average of 2,956 (**Figure 1D**). Given the importance of prior-exposure to SARS-CoV-2 in the development of humoral immunity, we determined COVID-

expeirence of each sample based on both anti-N ELISA results as well as otherwise
unexplained increases in SARS-CoV-2 spike-binding antibody titers. When comparing average
pNT50 across the three viruses, we found that COVID-experienced individuals exhibited
significantly increased titers as compared to those who were COVID-naive (**Figure S1E**).
Interestingly, we found that while samples from COVID-naive donors also exhibited all four
levels of potency, the proportion of potent neutralizers (*narrow-potent, broad-potent, and broad-*
extra-potent) was higher in COVID-experienced donors (**Figure S1F, Table S1-3**).
145
Broad neutralizers harbor the highest levels of stem helix and fusion peptide antibodies.
Coronaviruses are highly diverse and classified into four genera, alphacoronaviruses,
betacoronaviruses, deltacoronaviruses and gammacoronaviruses. All coronaviruses enter cells
using their spike proteins, but the species tropism and cell receptor usage varies. Aligning the
spike sequences across all four genera by conservation[54] highlights that the RBD, the target
for most neutralizing antibodies, are not conserved across coronaviruses (**Figure 2A**). The most
conserved regions include the FP and the SH. Sera from the five groups of samples were
assessed for their ability to bind to the full-length spike, RBD, FP, or SH by ELISA. Anti-spike
(**Figure 2B**) and anti-RBD (**Figure 2C**) antibody endpoint titers were significantly higher in the
broad-extra-potent and *broad-potent* groups than in the *moderate* or *weak* groups, as expected.
Notably, the *broad-extra potent* group exhibited slightly lower spike-binding titers but higher
RBD-specific titers than the broad-potent group. Importantly, only the *broad-extra-potent* group
displayed significantly elevated antibody titers against FP (**Figure 2D**) and SH (**Figure 2E**)
compared with the *moderate* group, suggesting that the increased potency and breadth of these
samples may derive from antibodies targeting these conserved regions.. To determine the
influence of prior COVID exposure on the development of antibodies against these epitopes, we
compared the activity of COVID-naive or COVID-experienced samples across epitopes (**Figure**
S2). COVID-experienced samples had higher endpoint titers against FP and SH but lower titers
against RBD across most groups. Interestingly, in the *broad-extra-potent* group, COVID-
experienced samples showed significantly higher FP titers than COVID-naive samples, while
titers against full-length spike, RBD, and SH did not differ significantly (**Figure 2F**). These
results suggest that the enhanced neutralizing activity in COVID-experienced broad-extra-potent
samples may be driven by FP-directed antibodies.
169
RBD and fusion peptide specific antibodies correlate with neutralizing titer.

To investigate the effect of antigen specific antibodies on neutralizing titer we selected 8

broad-extra-potent donors who had multiple serum collections over time (**Table S4**). Donors

were older individuals with an average age of 71 as they came from a nursing home cohort. All

donor samples were assessed for their antibody titers against spike, RBD, FP and SH to

determine the amounts of antibody targeting each epitope. Known antibodies specific for each

epitope were used to establish standard curves to interpolate Unit/mL values for each sample. A

non-specific control antibody at the same serum IgG concentration was used to determine a

cutoff for background binding to each antigen (**Figure 3, left**). All samples tested were above

the cutoff for spike (**Figure 3A, left**) and RBD (**Figure 3B, left**), but only 11 samples reached

the FP cutoff threshold and 9 samples reached the SH cutoff threshold (**Figure 3C, D**). To

assess whether antigen-specific antibodies had an impact on SARS-CoV-2 neutralizing titer,

correlation matrices were created for anti-spike (**Figure 3A**), anti-RBD (**Figure 3B**), anti-FP

(**Figure 3C**) and anti-SH (**Figure 3D**) binding measurements. Correlation matrices only

contained samples falling above their respective background levels to prevent bias by samples

below the limit of detection. Despite the limited sample size, RBD and FP binding titers both

correlated with the WT SARS-CoV-2 spike neutralizing titer, while spike and SH binding titers

did not correlate with neutralization.

Given the correlations with neutralizing titer, we sought to understand the effect of

vaccination on the development of antigen specific antibodies with our cohort. Generally, each

vaccine dose increased SARS-CoV-2 spike and RBD specific antibodies, while antibody

responses went down only after the first boost but remained high after subsequent doses.

(**Figure S3A, B**). While antibodies targeting SH increased in some donors following vaccination,

antibodies targeting FP did not change in this set of donors (**Figure S3C, D**). Unsurprisingly,

SARS-CoV-2 vaccination showed no impact on the neutralizing titers of the alphacoronaviruses

NL63 (**Figure S3E**) or 229E (**Figure S3F**), and no donor was able to neutralize MERS,

irrespective of vaccination (**Figure S3G**). This suggests that vaccine-induced breadth extends to

SARS-CoV-2 variants and closely related viruses, it does not extend to alphacoronaviruses or

MERS.

Fusion peptide antibodies can contribute to neutralization breadth.

To investigate the contributions to breadth of RBD, FP, and SH-specific antibodies, we

selectively depleted a subset of samples which had sufficient sera and high neutralizing activity

in Figure 3, using SARS-CoV-2 RBD domain or peptides coupled to magnetic beads (**Figure

4A**). Mock depletions were performed by mixing the uncoupled beads with serum without

antigen. Depletions were highly selective against the depleting antigen for both his-tagged WT
SARS-CoV-2 RBD (**Figure S4A**), and maleimide coupled FP and SH (**Figure S4B**)**.** We
selected a subset of samples with the highest neutralizing activity, 8 of which potently bound FP
and 6 of which potently bound SH, for depletion with each respective antigen (**Figure S4C, D**).
Overall, depletion of FP or SH-specific antibodies had a minimal effect on the neutralizing titers
of samples against both SARS-CoV-2 (**Figure S4E**) and SARS-CoV (**Figure S4F**). However, a
few samples (FP3, FP6) had slightly reduced neutralizing activity against both SARS-CoV and
SARS-CoV-2 when depleted for FP-specific antibody binding while a single sample had slightly
reduced neutralizing activity against both viruses after SH Depletion (SH4).

It has been previously shown that SARS-CoV-2 RBD depletion of sera can remove the
majority of neutralizing activity[47–49,55,56]. To determine whether this would also be the case with
potent neutralizing sera, we depleted 17 potently neutralizing samples using SARS-CoV-2 RBD
(**Figure S4G**). Of note, RBD-depleted serum samples 3,9,10,12,14,15, and 17 retained some
neutralizing activity against SARS-CoV-2 (**Figure 4B**), while RBD-depleted samples 3 and 17
retained substantial neutralizing activity against SARS-CoV (**Figure 4C**). These results suggest
that these samples harbored non-RBD, cross-reactive, neutralizing antibodies. As both sample
3 and 17 exhibited potent FP binding, the SARS-CoV-2 RBD-depleted samples were further
depleted to remove FP-binding antibodies (**Figure S4H**). While sample 17 retained some
neutralizing activity to SARS-CoV-2 (**Figure 4D**), both samples lost all neutralizing activity
against SARS-CoV (**Figure 4E**), suggesting that FP-specific responses in these samples
contributed to broad neutralizing activity.

Fusion peptide specific antibodies arise only from natural infection
Given the variability of FP-specific antibody levels we measured across donor samples,
we sought to determine when FP-specific antibodies arose. Using a cohort of pre-vaccine
COVID-experienced serum samples (**Table S5**), we found that more severe COVID infections
led to higher FP-specific antibody levels. (**Figure 5A**). However, we found no significant
differences in FP titers regardless of age (**Figure S5A**), race (**Figure S5B**) or biological sex
(**Figure S5C**).

We next sought to determine the effect of vaccinations on FP-specific antibody
elicitation. Donor samples were gathered from aged-matched cohorts containing older
individuals to test for FP-specific responses by ELISA (**Table S5**). COVID-naive and COVID-
experienced donors were first compared to determine whether FP-specific antibodies could be
detected in sera obtained before SARS-CoV-2 vaccines were available (**Figure 5B**). As

expected, donors who were COVID-experienced had significantly higher levels of FP-specific
antibodies than naive donors, suggesting that FP-specific antibodies were not common prior to
infection. To assess FP-specific antibody responses in donors who had been vaccinated,
samples from a vaccinated cohort of COVID-naive or COVID-experienced donors were
analyzed by ELISA. Vaccinated COVID-experienced donors had significantly higher levels of
FP-specific antibodies than those who were COVID-naive (**Figure 5C**). Separately, samples
obtained from a longitudinal cohort of COVID-naive donors from pre-vaccination to XBB.1.5
booster (**Table S5**) were tested for FP-specific antibodies. Interestingly, all COVID-naive donors
in this cohort had low levels of FP-specific antibodies irrespective of vaccination or boosting
(**Figure 5D**). However, longitudinal samples obtained from COVID-naive donors who
experienced breakthrough infection between their WT booster and bivalent vaccines, showed a
significant increase in FP-specific antibodies after infection (**Figure 5E**). This cohort also
exhibited an apparent decrease in FP-specific antibodies after bivalent vaccines and XBB.1.5
booster, though these decreases did not reach statistical significance. Together, these results
suggest that COVID infection, rather than vaccination, plays an important role in the
development of FP-specific antibodies. These findings suggest that mRNA vaccines do not
effectively elicit FP-specific responses and may reduce these responses when they arise as a
consequence of breakthrough infection.

Discussion

We sought to uncover how broad neutralization of SARS-CoV-2 and related coronaviruses developed following vaccination or infection and assessed the contribution of various spike epitopes to broad recognition. To this end, we determined the neutralization potency of hundreds of donors to find those with the most potent and broad neutralization. We found that neutralization activity in sera from *broad-extra-potent* neutralizers predominantly arises from RBD-specific antibodies as has been previously reported[57]. However, *broad-extra-potent* neutralizers also had the highest levels of FP and SH-specific antibodies. Moreover, among the *broad-extra-potent* samples, only RBD and FP-specific antibodies correlated with neutralizing titer. Despite increases in spike and RBD antibodies that were observed over multiple vaccine administrations, there was no correlation between vaccination and the development of FP and SH-specific responses. In line with this, neutralization breadth driven by vaccination extended to SARS-CoV-2 variants and SARS-like viruses, but did not extend to more distantly related beta and alpha coronaviruses.

Depletion of SARS-CoV-2 RBD-specific antibodies drastically reduced neutralization potency of sera, while FP-specific depletion resulted in only minimal effects, suggesting that the vast majority of neutralization can be attributed to RBD-specific humoral immunity. However, rare donors maintained substantial neutralizing titers against SARS-CoV-2 and SARS-CoV after RBD-specific depletion, indicating the presence of cross-reactive neutralizing antibodies targeting an epitope outside of RBD. Serial depletion of RBD followed by FP resulted in loss of all neutralizing activity, confirming the potential for FP-specific antibodies to contribute to neutralization activity. Our results agree with previously published work showing that depletion of convalescent donor serum with a linear peptide including the FP reduced neutralization titers by only 20%[58]. Additionally, our results suggest the activity of RBD-specific antibodies can mask FP-directed neutralizing antibodies, and that RBD depletion is necessary to enable their detection. This is especially true given the wide range of neutralization potencies of monoclonal FP-specific antibodies against SARS-CoV-2[43–46].

Given their potential as broad-spectrum treatments against coronaviruses, we sought to determine the source of FP-specific antibody development. Comparing COVID-naive and COVID-experienced cohorts, we found a clear, significant increase in FP-specific antibodies in COVID-experienced donors, suggesting that these antibodies primarily arise from natural infection. It has been shown that FP-specific antibodies lack binding to recombinantly expressed spikes, which contain either 2 or 6 proline mutations to stabilize the trimer[46]. Importantly, mRNA vaccines all encode spike proteins with the 2 proline mutations, which may contribute to their

lack of elicitation of FP-specific antibodies in vaccinated, COVID-naive individuals. Indeed, we

found that repeated mRNA vaccination did not promote FP-specific antibody development,

whereas breakthrough infection significantly increased FP-specific responses. Interestingly,

subsequent vaccination after infection in the breakthrough cohort largely reduced FP-specific

antibody levels. While age, gender, and demographics were not correlated with FP-specific

antibody development, greater COVID severity tended to induce higher levels of FP-specific

antibodies. This may be due to the extremely high levels of spike-specific antibodies seen in

severe COVID cases as we and others have shown a correlation between the amount of spike-

specific antibodies and disease severity[59,60,60].

Our study predominantly utilized samples from a cohort of nursing home donors who

have been longitudinally profiled, highlighting a unique cohort which generally struggles to

maintain effective immunity against continued SARS-CoV-2 evolution. However, we were able

to find donors among these with very broad and potent neutralizing activity, demonstrating the

potential to create effective humoral responses. These results also highlight the deficiencies of

current mRNA vaccines for the generation of FP-specific broadly neutralizing coronavirus

antibodies, suggesting that new vaccine designs may be needed for broader coverage. Updated

domain-specific vaccines have demonstrated promising results in clinical trials[61], however,

these lack FP sequences. In contrast, S2-specific vaccines also have shown potential for

protection and contain the FP-region which may improve targeting of this epitope[62,63]. FP-

specific vaccines have been suggested for HIV as a means of specifically eliciting antibodies

against this target[64,65]. Whether similar vaccine designs presenting coronavirus FP could elicit

comparable humoral responses remains to be determined.

Although the COVID-19 pandemic has been declared over by the WHO[66,67], there are

still tens of thousands of cases and hundreds of deaths each day and the virus continues to

evolve to evade humoral immunity[68]. Additionally, the ever-present threat of a new zoonotic

transmission event, given the vast reservoir of SARS-like viruses that exist in animal

populations, highlights the need to develop more broadly effective vaccines. Development of

approaches capable of efficiently eliciting FP-specific antibodies would ensure the availability of

effective prophylaxis against future pandemic coronaviruses.

Limitations of the Study

This study is limited to the evaluation of serum neutralizing antibodies to the spike

protein using a pseudovirus-based neutralization assay, and does not take into account

neutralizing antibodies to other proteins including the N and M proteins which may contribute to

neutralizing breadth. Additionally, spike ELISAs used 2P-stabilized recombinant proteins, which

could underestimate the total spike antibodies. It is known that FP-specific antibodies bind 2P-

stabilized spikes with lower affinity than the native conformation of spike[69]. Our experiments

also utilized linear peptides to represent the FP and SH and therefore could be underestimating

the binding to these epitopes in the context of the native conformation of spike, however,

others[39,43–45] have used similar approaches for monoclonal antibody binding and for sorting of

individual memory B cells. Furthermore, we did not assess the role of vaccine-elicited cellular

immune responses mediated by T cells and NK cells, which play a key role in limiting disease

severity for vaccine recipients. We also did not assess other antibody-mediated functions such

as complement deposition, antibody-dependent cellular cytotoxicity, or antibody-dependent

cellular phagocytosis, which may contribute to protection even in the absence of neutralizing

antibodies.

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by Alejandro Balazs (abalazs@mgh.harvard.edu).

Materials Availability

Plasmids generated in this study will be available through Addgene. Recombinant proteins, peptides, and antibodies are available from their respective sources.

Data and Code Availability

This study did not generate sequence data. Data generated in the current study (including neutralization measurements and flow cytometric files) have not been deposited in a public repository but are available from the corresponding author upon request. The code used to make the phylogenetic trees can be made available from the corresponding author upon request.

ACKNOWLEDGEMENTS, FUNDING SUPPORT

We wish to thank Michael Farzan, PhD, for providing ACE2-expressing 293T cells. This work was supported by the Peter and Ann Lambertus Family Foundation. A.B.B. was supported by NIAID R01s AI174875, AI174276, AI129709-03S1 the NIDA Avenir New Innovator Award DP2DA040254, the NIDA Avant-Garde Award 1DP1DA060607, a Massachusetts Consortium on Pathogenesis Readiness (MassCPR) grant, CDC subcontract 200-2016-91773-T.O.2 and a grant from Coalition for Epidemic Preparedness Innovations (CEPI).

AUTHOR CONTRIBUTIONS

Conceptualization: A.R., A.B.B.

Methodology: A.R., Y.C.

Samples: D.H.C., S.G., M.P

Investigation: A.R., Y.C., C.J.L, E.L, T.D.

Data Curation: A.R.

Writing – Original Draft: A.R.

Writing – Reviewing and Editing: A.R., C.J.L., A.B.B. edited the paper with input from co-authors.

DECLARATIONS OF INTEREST

A.B.B. is a founder of Cure Systems LLC. S. G. and D. H. C. are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines, Sanofi Pasteur and Seqirus to study influenza vaccines, Moderna to study respiratory infection, and GSK to study herpes zoster. S. G. is the recipient of an investigator-initiated grant to the university from Genentech on influenza antivirals; reports consulting for GSK, Janssen/Johnson&Johnson, Merck, Novavax, Moderna, Seqirus, Sanofi, and Vaxart; he has received honoraria for speaking for AstraZeneca, Pfizer, Seqirus, Sanofi; reports personal fees from Pfizer; and reports data and safety monitoring board fees from Longevoron and SciClone.

Disclaimer. The contents do not represent the views of the U.S. Department of Veterans Affairs or of the United States Government.

MAIN FIGURE TITLES AND LEGENDS

Figure 1: Broad neutralizers have extensive breadth across related Beta coronaviruses.

(A) A cohort of 382 donor samples was divided into four groups based on neutralization potency

(average of n = 2 technical replicates) against SARS-CoV-2 WT and the BA.1 and BA.5

variants, with a detection limit of pNT50 = 8748. Samples with pNT50 > 2000 against WT and >

1500 against both BA.1 and BA.5 were classified as Broad-Potent. Samples with at least one

but not all pNT50 values exceeding these thresholds were classified as Narrow-Potent.

Samples with pNT50 < 300 against WT and < 100 against BA.1 and BA.5 were classified as

Weak, and all remaining samples were classified as Moderate. Because data did not pass

normality tests (Shapiro-Wilk p < 0.05), non-parametric analyses were used. pNT50 values

were compared using the Kruskal-Wallis test followed by Dunn's multiple comparisons test (* =

P<0.0332, ** = P<0.0021, ***= P<0.0002, ****= P<0.0001).

(B) A subset of donor samples from each group were subject to our high throughput

neutralization assay against SARS-CoV-2, variants, Beta Coronaviruses, and other distantly

related coronaviruses for neutralizing activity (average of n = 2 technical replicates).

(C) A subset of broad-potent samples was further tested against Beta Coronaviruses (excluding

MERS) with a much higher threshold for neutralizing activity (average of n = 2 technical

replicates).

(D) Sera from (C) were subdivided into broad-extra-potent and broad-potent groups based on

average neutralizing activity across the tested viruses using the cutoff pNT50 = 5000. Because

the data were approximately normally distributed (Shapiro-Wilk p > 0.05), neutralization titers

were compared between the groups using an unpaired two-tailed t-test with Welch's correction

for unequal variances.

Figure 2: Broad-extra-potent sera have the highest levels of RBD, FP and SH antibodies.

(A) Conservation of the amino acids within the spike protein generated using consurf[54] from

(PDB 6XR859 https://doi.org/10.2210/pdb6xr8/pdb). The sequences fed into the algorithm

include 59 coronavirus spike sequences representing all four clades. RBD = Receptor Binding

Domain, NTD = N-Terminal Domain, FP = Fusion Peptide, SH = Stem Helix.

(B-E) Results from ELISA assessing the antibody endpoint titers of plasma from 21 broad-extra-

potent, 16 broad-potent, 11 narrow-potent, 17 moderate and 9 weak donors. Antibody endpoint

titers (average of n = 2 technical replicates) were assessed against an S2P Stabilized spike (B),

Receptor Binding Domain (C), Fusion Peptide (D), or Stem Helix Peptide (E). Antibody endpoint

titer represents the maximum interpolated dilution that can still bind the antigen. The endpoint titers were evaluated at a top dilution of 100-fold with seven additional 3-fold serial dilutions. The wells incubated with no plasma incubation were used as controls, and cut-off values (used for interpolation) were defined as 2.1X the OD450 of the controls. Representative data from two independent experiments is shown. Because data did not pass normality tests (Shapiro-Wilk p < 0.05), non-parametric analyses were used. Endpoint titer values were compared using the Kruskal-Wallis test followed by Dunn's multiple comparisons test (* = P<0.0332, ** = P<0.0021, ***= P<0.0002, ****= P<0.0001).

(F) Broad-extra-potent data from Figure 2B-D were further divided into two groups based on COVID history. Samples from COVID-naïve donors were outlined in gray, and those from COVID-experienced donors were outlined in black. Endpoint titers were compared between groups using an unpaired two-tailed t-test with Welch's correction for unequal variances. ** = P<0.0021.

Figure 3: RBD and fusion peptide specific antibody titers correlate with neutralizing activity.

(A-D, left) Unit/mL (U/mL) of antigen specific antibody was assessed for a cohort of broad and potent neutralizers (average of n = 2 technical replicates). All U/mL were calculated using an antigen specific ELISA and were defined as the equivalent reactivity to 1 µg/mL binding of the following antibodies: RBD182 for Spike (A) and RBD (B), 76E1 for FP (C), S2P6 for SH (D). A negative control antibody (2A10) at the same concentration as the serum dilution was included to determine cutoff values to define background serum binding. Data below the cutoff were excluded from subsequent correlation analyses. (A-D, right) Log-log regression analyses were performed on neutralization versus anti-Spike IgG (A), anti-RBD IgG (B), anti-FP IgG (C), and anti-SH IgG (D). Pearson correlations were performed and R2 and p values are indicated.

Figure 4: Fusion peptide antibodies contribute to neutralization breadth.

(A) Schematic detailing our antigen depletion protocol. Briefly, his-tag or maleimide binding magnetic beads are pre-coupled to the antigen/peptide and mixed with serum. After an incubation the magnetic beads are pulled away using a magnet and serum is collected for downstream assays. Mock depletion is done by mixing serum and beads with no antigen (Created in BioRender).

(B-C) Serum samples with high neutralizing activity were subject to RBD based depletion using his-tagged beads or mock depletion using beads with no RBD bound. Mock and depleted serum

was tested for neutralizing activity (average of n = 2 technical replicates) against SARS-CoV-2 (C) and SARS-CoV (D).

(D-E) Serum samples with remaining neutralizing activity against both SARS-CoV-2 and SARS-CoV from (B-C) were subject to further depletion with the fusion peptide and tested for remaining neutralizing activity (average of n = 2 technical replicates) to SARS-CoV-2 (D) and SARS-CoV (E) after double depletion.

Figure 5: Fusion peptide antibodies develop in response to natural infection.

(A) Anti-Fusion Peptide ELISA for a cohort of COVID-experienced pre-vaccination timepoints split into non-hospitalized and hospitalized (average of n = 2 technical replicates). Limit of detection line is defined as the background binding of a negative control antibody to the FP for that experiment. Because the data did not follow a normal distribution (Shapiro-Wilk $p < 0.001$), differences between these groups were analyzed using the Mann-Whitney U test (two-tailed). * = $P<0.0332$.

(B) Anti-Fusion Peptide ELISA (average of n = 2 technical replicates) for pre-vaccination serum samples for donors who were naïve or who had been infected with COVID. A Mann Whitney Two tailed T-test was performed to assess significance. ****= $P<0.0001$.

(C) Anti-Fusion Peptide ELISA (average of n = 2 technical replicates) for post-vaccination serum samples for donors who were naïve after 2-6 vaccines or who were COVID-experienced at the timepoint and had received between 2-6 vaccines. A Mann Whitney Two tailed T-test was performed to assess significance. ***= $P<0.0002$.

(D) Fusion peptide ELISA (average of n = 2 technical replicates) was performed for a cohort of COVID naïve donors at various stages of vaccination. No significance was seen between groups in the development of FP specific antibodies. Limit of detection line is defined as the background binding of a negative control antibody to the FP for that experiment.

(E) Anti-Fusion Peptide ELISA (average of n = 2 technical replicates) for longitudinal timepoints of donors who had a breakthrough infection between 2nd vaccine and bivalent. Pre-Breakthrough (Pre-BT) indicates the time point closest to breakthrough infection (BT) timepoint. A Kruskal Wallis one-way ANOVA was performed with Dunn's correction for multiple comparisons (* = $P<0.0332$, ** = $P<0.0021$, ***= $P<0.0002$, ****= $P<0.0001$). For A-E U/mL is defined as the reactivity seen by 1 µg/mL of 76E1 antibody. Cutoffs were determined by binding of a negative control antibody (2A10).

STAR ◻ METHODS

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human subjects

Use of human samples was approved by Partners Institutional Review Board (protocol 2020P002274). The current analysis is part of an ongoing study in which NH residents are consented directly or through their legally authorized representative if needed and serially sampled before and after each SARS-CoV-2 vaccine dose. This analysis includes data collected between September 29, 2021, and June 7, 2023. Residents who received SARS-CoV-2 mRNA vaccines [(BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)] were included, and those who received the Ad26.COV2.S (Janssen) vaccine were excluded. Participants received their first booster dose 8–9 months after the primary vaccination series, their second booster 4 to 6 months after their first booster and third booster 4 to 7 months after their second booster. We report results from blood samples obtained at time points prior to and following one, two or three booster doses. All donor genders were self-reported.

Cell lines

HEK 293T cells (ATCC) were cultured in DMEM (Corning) containing 10% fetal bovine serum (VWR), and penicillin/streptomycin (Corning) at 37°C/5% CO_2. 293T-ACE2 cells were a gift from Michael Farzan (Scripps Florida) and Nir Hacohen (Broad Institute) and were cultured under the same conditions. Confirmation of ACE2 expression in 293T-ACE2 cells was done via flow cytometry. hDPP4-293T and hANPEP-293T were produced in-house and expression of hDPP4 and hANPEP was confirmed via flow cytometry.

METHOD DETAILS

To create variant spike expression plasmids, we performed multiple PCR fragment amplifications utilizing oligonucleotides containing each desired mutation (Integrated DNA Technology) and utilized overlapping fragment assembly to generate the full complement of mutations for each strain. PCR reactions were done with Platinum SuperFI II (Thermofisher) according to the manufacturer's protocol for reaction size and thermocycler protocol. Importantly, we generate these mutations in the context of our previously described (Garcia-Beltran *et al.* 2020[56]) codon-optimized SARS-CoV-2 spike expression plasmid harboring a deletion of the C-terminal 18 amino acids that was previously demonstrated to result in higher pseudovirus titers. Assembled fragments were inserted into NotI/XbaI digested pTwist-CMV-

BetaGlobin-WPRE-Neo vector utilizing the In-Fusion HD Cloning Kit (Takara) according to the

manufacturer's protocol. In-Fusion reactions were transformed into Mix and Go DH5Alpha cells

(Zymo Research) according to the manufacturer's protocol and colonies were grown overnight

at 37°C to generate plasmid DNA purified using a standard miniprep protocol (Qiagen). All

resulting plasmid DNA utilized in the study was verified by whole-plasmid deep sequencing

(Illumina or Primordium Labs) to confirm the presence of only the intended mutations and maxi-

prepped (Macherey-Nagel) to ensure high quality, high concentrated DNA.

528   Construction of fusion and stem helix peptides

529   All peptides used in this manuscript were synthesized by GenScript with a C terminal cysteine

530   for maleimide conjugation. The following sequences were used for the Fusion Peptide and Stem

531   Helix: SKPSKRSFIEDLLNKVTLADAGC (FP), and DSFKEELDKYFKNHTSC (SH). Peptides

532   were resuspended in the manufacturer recommended buffer, aliquoted into tubes, and stored at

533   -20°C when not in use.

535   SARS-CoV-2 pseudovirus neutralization assay

To compare the neutralizing activity of vaccine sera against coronaviruses, we produced

lentiviral particles pseudotyped with different spike proteins as previously described (Garcia-

Beltran *et al.* 2020[59]). Briefly, pseudoviruses were produced in 293T cells by PEI transfection of

a lentiviral backbone encoding CMV-Luciferase-IRES-ZsGreen as well as lentiviral helper

plasmids and each spike variant expression plasmid. Following collection and filtering,

production was quantified by titering via flow cytometry on 293T-ACE2 cells. Neutralization

assays and readout were performed on a Fluent Automated Workstation (Tecan) liquid handler

using 384-well plates (Grenier). Three-fold serial dilutions ranging from 1:12 to 1:8,748 were

performed for each serum sample before adding 125–250 infectious units of pseudovirus for 1

hr. Subsequently, 293T-ACE2 cells containing polybrene at 8 µg/mL were added to each well

and incubated at 37°C/5% CO_2 for 48-60 hrs. Following transduction, cells were lysed using a

luciferin-containing buffer (Siebring-van Olst *et al.* 2013[70]) and shaken for 5 min prior to

quantitation of luciferase expression within 1 hr of buffer addition using a Spectramax L

luminometer (Molecular Devices) or a Pherastar with Microplate Stacker (BMG Labtech).

Percent neutralization was determined by subtracting background luminescence measured in

cell control wells (cells only) from sample wells and dividing by virus control wells (virus and

cells only). Data was analyzed using Graphpad Prism and pNT_{50} values were calculated by

taking the inverse of the 50% inhibitory concentration value for all samples with a neutralization

value of 80% or higher at the highest concentration of serum.

Titering

To determine the infectious units of pseudotyped lentiviral vectors, we plated 400,000 293T-
ACE2 cells per well of a 12-well plate. 24 h later, three ten-fold serial dilutions of neat
pseudovirus supernatant were made in 100 µL, which was then used to replace 100 µL of
media on the plated cells. Cells were incubated for 48 h at 37°C/5% CO_2 to allow for expression
of the ZsGreen reporter gene and harvested with Trypsin-EDTA (Corning). Cells were
resuspended in PBS supplemented with 2% FBS (PBS+), and analyzed on a Stratedigm
S1300Exi Flow Cytometer to determine the percentage of ZsGreen-expressing cells. Infectious
units were calculated by determining the percentage of infected cells in wells exhibiting linear
decreases in transduction and multiplying by the average number of cells per well determined at
the initiation of the assay. At low MOI, each transduced ZsGreen cell was assumed to
represent a single infectious unit.

hANPEP and hDPP4 293T Cell Line Production

To create cell lines that could be used in the high throughput neutralization assay we first cloned
the known cellular receptors hDPP4 (MERS) and hANPEP (229E) into a lentiviral vector
backbone from cDNA. Lentivirus was then produced using the same plasmids as the
pseudovirus without the spike or fLuc-ZsGreen vectors. 293T cells were seeded at 400,000
cells/well one day before, media was removed and an equal quantity of lentivirus was added to
cells. After 48 hours, cells were counted and diluted to 1 cell/well of 2 X 96 well plates. Single
cell clones were then grown up for 2 weeks and assessed for surface expression of the
indicated receptor by flow cytometry using the following stains CD26-PE-Cy7 (Biolegend
302713), or CD13-BV785 (Biolegend 301725). The highest expressing single clone was then
grown up to make the cell line and frozen down in 90% FBS 10% DMSO for further uses.

Endpoint ELISA

Endpoint ELISAs were determined as follows: 96-well NUNC MaxiSorp ELISA plates
(ThermoFisher) were coated with either 0.8 µg/mL purified S2P stabilized spike protein, 1 µg/mL
purified RBD (kindly provided by Aaron Schmidt, Jared Feldman, and Blake Hauser) or 2 µg/mL
synthesized Stem-Helix or Fusion-Peptide (GenScript). Plates were washed with a wash buffer
consisting of 50 mM Tris (pH 8.0) (Sigma), 140 mM NaCl (Sigma), and 0.05% Tween-20
(Sigma). Plates were incubated with a blocking buffer consisting of 1% BSA (Seracare), 50 mM

Tris (pH 8.0), and 140 mM NaCl for 30 min at room temperature, and then washed. Serum
samples were diluted 1:100 with a dilution buffer consisting of 1% BSA, 50 mM Tris (pH 8.0),
140 mM NaCl, and 0.05% Tween-20. Samples were added to corresponding wells and
incubated for 1 hr at room temperature, followed by washing. Anti-human IgG-HRP (1:25,000)
specific antibodies (Bethyl) were then used to detect bound serum antibodies and were diluted
as indicated. These were added to each plate and incubated for 30 min at room temperature.
After washing, detection was done with a TMB 2-Component Microwell Peroxidase Substrate
Kit (VWR). Substrate B and Sample were mixed at a 1:1 ratio following manufacturer
instructions and then added to each well and incubated for ~5 min before stopping with 3 M

H_2SO_4. Buffer compositions, reagent concentrations and incubation times and temperatures

were optimized in separate experiments for each analyte to maximize signal-to-noise ratio.
Optical density (O.D.) was measured at 450 nm with subtraction of the O.D. at 570 nm as a
reference wavelength on a SpectraMax ABS microplate reader. Antibody endpoint titer
represents the maximum interpolated dilution that can still bind the antigen. The endpoint titers
were evaluated at a top dilution of 100-fold with seven additional 3-fold serial dilutions. The
wells incubated with no plasma incubation were used as controls, and cut-off values (used for
interpolation) were defined as 2.1X the OD450 of the controls.
605

Quantitative ELISA
ELISAs were performed identically to endpoint ELISAs. A standard curve was generated using
the following antibodies and the WT SARS-CoV-2 spike ectodomain (SinoBiologic) was used for
coating at 0.8 µg/mL: RBD182 antibody as a control for Spike and SARS-CoV-2 RBD binding,
S2P6 as a control for Stem Helix binding, and 76E1 as a control for Fusion Peptide binding.
Anti-RBD and anti-spike antibody levels were calculated by interpolating onto the standard
curve and correcting for sample dilution; one unit per mL (U/mL) was defined as the equivalent
reactivity seen by 1 µg/mL of a SARS-CoV-2 RBD antibody (RBD182) which was isolated from
human donor PBMCs). Anti-SH and anti-FP antibodies were calculated similarly; one U/mL of
SH antibody was defined as the equivalent reactivity seen by 1 µg/mL S2P6 while one U/mL of
FP antibody was defined as the equivalent reactivity seen by 1 µg/mL 76E1.
617

Depletion Protocol RBD
Dynabeads (Thermofisher) were washed three times according to the manufacturer protocol
and resuspended in PBS + 0.05% BSA. 5 µL of serum was added to molar equivalents of

purified RBD (kindly provided by Aaron Schmidt, Jared Feldman, and Blake Hauser). Mock
depleted sera was added to an equivalent volume of PBS + 0.05% BSA. Serum and RBD or
serum and PBS + 0.05% BSA were incubated at room temperature for 1 hour. Beads were
added to a magnet for 5 minutes, the supernatant was removed, and beads were resuspended
in the RBD + Serum or Mock depletion mixture before incubating for 30 minutes at room
temperature. Depletions were then placed on a magnetic strip for 5 minutes and supernatant
was collected for downstream assays. RBD depletion was confirmed by an ELISA of mock and
depleted samples for binding to the RBD.

Depletion Protocol Stem Helix and Fusion Peptide
Maleimide activated beads (Cube Biotech) were washed three times according to the
manufacturer's protocols in coupling buffer. 3 mg of peptide was then added to the coupling
buffer to a final volume of 1.5 mL in an Eppendorf tube. Beads were then resuspended in the
coupling buffer with a peptide and incubated on a thermoshaker overnight at 4°C or at 20°C for
2 hours. Beads were then incubated on a magnetic strip for 2 minutes before being washed 3
more times in a coupling buffer and then once in 1 mL distilled water. Finally, conjugated beads
were resuspended in 500 µL of storage buffer (Dissolve 2.1g of $NaHCO_3$ in 150 mL water,
adjust pH to 7.5 then add 1 mL sodium azide (5% w/v) and fill up to 250 mL with water) and
stored at 4°C for future use. Before depletion, beads were washed 3 times with PBS + 0.05%
BSA and then resuspended in 5 µL Serum diluted in 45 µL PBS + 0.05% BSA before incubating
at room temperature for 30 minutes. Beads were then incubated on a magnetic strip for 5
minutes before supernatant was removed for future analysis. Mock depletions were performed
as above only with unconjugated beads. Depleted samples were confirmed by ELISA for both
efficiency and selectivity of depletion.

QUANTIFICATION AND STATISTICAL ANALYSIS
Data and statistical analyses were performed using GraphPad Prism 10.2.2. Flow cytometry
data was analyzed using FlowJo 10.10. One-way Anova, Kruskal-Wallis test followed by Dunn's
multiple comparisons test, unpaired two-tailed t-test with Welch's correction for unequal
variances, and Mann Witney two-tailed T-tests were used in the indicated figures. Statistical
significance was defined as $p < 0.05$.

REFERENCES

1. COVID - Coronavirus Statistics - Worldometer
    https://www.worldometers.info/coronavirus/#google_vignette.

2. Kung, S., Doppen, M., Black, M., Braithwaite, I., Kearns, C., Weatherall, M., Beasley, R., and Kearns, N. (2021). Underestimation of COVID-19 mortality during the pandemic. ERJ Open Res. *7*, 00766–02020. https://doi.org/10.1183/23120541.00766-2020.

3. Greaney, A.J., Eguia, R.T., Starr, T.N., Khan, K., Franko, N., Logue, J.K., Lord, S.M., Speake, C., Chu, H.Y., Sigal, A., et al. (2022). The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS Pathog. *18*, e1010592. https://doi.org/10.1371/journal.ppat.1010592.

4. Cox, M., Peacock, T.P., Harvey, W.T., Hughes, J., Wright, D.W., Willett, B.J., Thomson, E., Gupta, R.K., Peacock, S.J., Robertson, D.L., et al. (2023). SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. *21*, 112–124. https://doi.org/10.1038/s41579-022-00809-7.

5. Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022). Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature *602*, 657–663. https://doi.org/10.1038/s41586-021-04385-3.

6. Starr, T.N., Greaney, A.J., Dingens, A.S., and Bloom, J.D. (2021). Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. *2*, 100255. https://doi.org/10.1016/j.xcrm.2021.100255.

7. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. *383*, 2603–2615.

8. Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021). Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. *384*, 2187–2201.

9. Heath, P.T., Galiza, E.P., Baxter, D.N., Boffito, M., Browne, D., Burns, F., Chadwick, D.R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N. Engl. J. Med. *385*, 1172–1183.

10. Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. *384*, 403–416. https://doi.org/10.1056/NEJMoa2035389.

11. Hsieh, C.-L., Goldsmith, J.A., Schaub, J.M., DiVenere, A.M., Kuo, H.-C., Javanmardi, K., Le, K.C., Wrapp, D., Lee, A.G., Liu, Y., et al. (2020). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science, eabd0826. https://doi.org/10.1126/science.abd0826.

12. Garcia-Beltran, W.F., Lam, E.C., St. Denis, K., Nitido, A.D., Garcia, Z.H., Hauser, B.M., Feldman, J., Pavlovic, M.N., Gregory, D.J., Poznansky, M.C., et al. (2021). Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell *184*, 2372-

692   2383.e9. https://doi.org/10.1016/j.cell.2021.03.013.

13. Plante, J.A., Liu, Y., Liu, J., Xia, H., Johnson, B.A., Lokugamage, K.G., Zhang, X., Muruato, A.E., Zou, J., Fontes-Garfias, C.R., et al. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature *592*, 116–121. https://doi.org/10.1038/s41586-020-2895-3.

14. Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I.A.T.M., Datir, R., Collier, D.A., Albecka, A., Singh, S., et al. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature *599*, 114–119. https://doi.org/10.1038/s41586-021-03944-y.

15. Lasrado, N., Collier, A.-R.Y., Hachmann, N.P., Miller, J., Rowe, M., Schonberg, E.D., Rodrigues, S.L., LaPiana, A., Patio, R.C., Anand, T., et al. (2023). Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine *41*, 6904–6909. https://doi.org/10.1016/j.vaccine.2023.10.051.

16. Miller, J., Hachmann, N.P., Collier, A.Y., Lasrado, N., Mazurek, C.R., Patio, R.C., Powers, O., Surve, N., Theiler, J., Korber, B., et al. (2023). Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. N. Engl. J. Med. *388*, 662–664.

17. Jeworowski, L.M., Mühlemann, B., Walper, F., Schmidt, M.L., Jansen, J., Krumbholz, A., Simon-Lorière, E., Jones, T.C., Corman, V.M., and Drosten, C. (2024). Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Eurosurveillance *29*, 2300740. https://doi.org/10.2807/1560-7917.ES.2024.29.2.2300740.

18. Roederer, A.L., Cao, Y., St Denis, K., Sheehan, M.L., Li, C.J., Lam, E.C., Gregory, D.J., Poznansky, M.C., Iafrate, A.J., Canaday, D.H., et al. (2024). Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity. Cell Rep. Med., 101850. https://doi.org/10.1016/j.xcrm.2024.101850.

19. Bar-On, Y.M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021). Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N. Engl. J. Med. *385*, 1393–1400.

20. Link-Gelles, R. (2022). Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022. MMWR Morb. Mortal. Wkly. Rep. *71*. https://doi.org/10.15585/mmwr.mm7148e1.

21. Tartof, S.Y., Slezak, J.M., Puzniak, L., Hong, V., Frankland, T.B., Ackerson, B.K., Takhar, H., Ogun, O.A., Simmons, S., Zamparo, J.M., et al. (2022). BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect. Dis. *22*, 1663–1665. https://doi.org/10.1016/S1473-3099(22)00692-2.

22. Uraki, R., Ito, M., Kiso, M., Yamayoshi, S., Iwatsuki-Horimoto, K., Furusawa, Y., Sakai-Tagawa, Y., Imai, M., Koga, M., Yamamoto, S., et al. (2023). Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect. Dis. *23*, 402–403. https://doi.org/10.1016/S1473-3099(23)00070-1.

23. Gayed, J., Diya, O., Lowry, F.S., Xu, X., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Lu, C., et al. (2024). Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted

BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial. Vaccines *12*,
118. https://doi.org/10.3390/vaccines12020118.

24. Hansen, C.H., Moustsen-Helms, I.R., Rasmussen, M., Søborg, B., Ullum, H., and
Valentiner-Branth, P. (2024). Short-term effectiveness of the XBB.1.5 updated COVID-19
vaccine against hospitalisation in Denmark: a national cohort study. Lancet Infect. Dis. *24*,
e73–e74. https://doi.org/10.1016/S1473-3099(23)00746-6.

25. Chalkias, S., McGhee, N., Whatley, J.L., Essink, B., Brosz, A., Tomassini, J.E., Girard, B.,
Wu, K., Edwards, D.K., Nasir, A., et al. (2023). Safety and Immunogenicity of XBB.1.5-
Containing mRNA Vaccines. Preprint at medRxiv,
https://doi.org/10.1101/2023.08.22.23293434 https://doi.org/10.1101/2023.08.22.23293434.

26. Link-Gelles, R. (2024). Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5)
COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable
to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing
Community Access to Testing Program, United States, September 2023–January 2024.
MMWR Morb. Mortal. Wkly. Rep. *73*. https://doi.org/10.15585/mmwr.mm7304a2.

27. Research, C. for B.E. and (2024). Updated COVID-19 Vaccines for Use in the United States
Beginning in Fall 2024. FDA.

28. Xu, K., An, Y., Liu, X., Xie, H., Li, D., Yang, T., Duan, M., Wang, Y., Zhao, X., Dai, L., et al.
(2024). Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine
sera. Npj Vaccines *9*, 1–6. https://doi.org/10.1038/s41541-024-01016-6.

29. Kaku, Y., Uriu, K., Kosugi, Y., Okumura, K., Yamasoba, D., Uwamino, Y., Kuramochi, J.,
Sadamasu, K., Yoshimura, K., Asakura, H., et al. (2024). Virological characteristics of the
SARS-CoV-2 KP.2 variant. Lancet Infect. Dis. *0*. https://doi.org/10.1016/S1473-
3099(24)00298-6.

30. GISAID Initiative https://www.epicov.org/epi3/frontend#b40c.

31. Roederer, A.L., Cao, Y., Denis, K.S., Sheehan, M.L., Li, C.J., Lam, E.C., Gregory, D.J.,
Poznansky, M.C., Iafrate, A.J., Canaday, D.H., et al. (2024). Ongoing evolution of SARS-
CoV-2 drives escape from mRNA vaccine-induced humoral immunity. Preprint at medRxiv,
https://doi.org/10.1101/2024.03.05.24303815 https://doi.org/10.1101/2024.03.05.24303815.

32. Planas, D., Staropoli, I., Planchais, C., Yab, E., Jeyarajah, B., Rahou, Y., Prot, M., Guivel-
Benhassine, F., Lemoine, F., Enouf, V., et al. (2024). Escape of SARS-CoV-2 Variants
KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Pathog. Immun. *10*, 1–11.
https://doi.org/10.20411/pai.v10i1.752.

33. Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting
Announcement - 05/16/2024 (2024). FDA. https://www.fda.gov/advisory-
committees/advisory-committee-calendar/vaccines-and-related-biological-products-
advisory-committee-may-16-2024-meeting-announcement.

34. Walsh, J.A., and Maher, C. (2011). Economic Implications of Influenza and Influenza
Vaccine. In Influenza Vaccines for the Future, R. Rappuoli and G. Del Giudice, eds.
(Springer), pp. 425–440. https://doi.org/10.1007/978-3-0346-0279-2_19.

35. Glennerster, R., Kelly, T., McMahon, C.T., and Snyder, C.M. Quantifying the Social Value of
a Universal COVID-19 Vaccine and Incentivizing Its Development.

36. Starr, T.N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y.-J., Addetia, A., Pinto, D.,
Beltramello, M., Hernandez, P., Greaney, A.J., et al. (2021). SARS-CoV-2 RBD antibodies
that maximize breadth and resistance to escape. Nature *597*, 97–102.
https://doi.org/10.1038/s41586-021-03807-6.

37. Wang, Y., Yan, A., Song, D., Duan, M., Dong, C., Chen, J., Jiang, Z., Gao, Y., Rao, M.,
Feng, J., et al. (2024). Identification of a highly conserved neutralizing epitope within the
RBD region of diverse SARS-CoV-2 variants. Nat. Commun. *15*, 842.
https://doi.org/10.1038/s41467-024-45050-3.

38. Starr, T.N., Greaney, A.J., Hannon, W.W., Loes, A.N., Hauser, K., Dillen, J.R., Ferri, E.,
Farrell, A.G., Dadonaite, B., McCallum, M., et al. (2022). Shifting mutational constraints in
the SARS-CoV-2 receptor-binding domain during viral evolution. Science *377*, 420–424.
https://doi.org/10.1126/science.abo7896.

39. Dacon, C., Peng, L., Lin, T.-H., Tucker, C., Lee, C.-C.D., Cong, Y., Wang, L., Purser, L.,
Cooper, A.J.R., Williams, J.K., et al. (2023). Rare, convergent antibodies targeting the stem
helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe *31*, 97-111.e12.
https://doi.org/10.1016/j.chom.2022.10.010.

40. Zhou, P., Song, G., Liu, H., Yuan, M., He, W., Beutler, N., Zhu, X., Tse, L.V., Martinez, D.R.,
Schäfer, A., et al. (2023). Broadly neutralizing anti-S2 antibodies protect against all three
human betacoronaviruses that cause deadly disease. Immunity *56*, 669-686.e7.
https://doi.org/10.1016/j.immuni.2023.02.005.

41. Pinto, D., Sauer, M.M., Czudnochowski, N., Low, J.S., Tortorici, M.A., Housley, M.P.,
Noack, J., Walls, A.C., Bowen, J.E., Guarino, B., et al. (2021). Broad betacoronavirus
neutralization by a stem helix–specific human antibody. Science *373*, 1109–1116.
https://doi.org/10.1126/science.abj3321.

42. Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., Li, W., Okba, N.M.A., Albulescu, I.,
Widjaja, I., van Dieren, B., Fernandez-Delgado, R., Sola, I., et al. (2021). A conserved
immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-
reactive monoclonal antibodies. Nat. Commun. *12*, 1715. https://doi.org/10.1038/s41467-
021-21968-w.

43. Sun, X., Yi, C., Zhu, Y., Ding, L., Xia, S., Chen, X., Liu, M., Gu, C., Lu, X., Fu, Y., et al.
(2022). Neutralization mechanism of a human antibody with pan-coronavirus reactivity
including SARS-CoV-2. Nat. Microbiol. *7*, 1063–1074. https://doi.org/10.1038/s41564-022-
01155-3.

44. Bianchini, F., Crivelli, V., Abernathy, M.E., Guerra, C., Palus, M., Muri, J., Marcotte, H.,
Piralla, A., Pedotti, M., Gasparo, R.D., et al. (2023). Human neutralizing antibodies to cold
linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Sci. Immunol. *8*,
eade0958. https://doi.org/10.1126/sciimmunol.ade0958.

45. Dacon, C., Tucker, C., Peng, L., Lee, C.-C.D., Lin, T.-H., Yuan, M., Cong, Y., Wang, L.,
Purser, L., Williams, J.K., et al. (2022). Broadly neutralizing antibodies target the

coronavirus fusion peptide. Science *377*, 728–735.
https://doi.org/10.1126/science.abq3773.

46. Low, J.S., Jerak, J., Tortorici, M.A., McCallum, M., Pinto, D., Cassotta, A., Foglierini, M.,
Mele, F., Abdelnabi, R., Weynand, B., et al. (2022). ACE2-binding exposes the SARS-CoV-
2 fusion peptide to broadly neutralizing coronavirus antibodies. Science *377*, 735–742.
https://doi.org/10.1126/science.abq2679.

47. Farrell, A.G., Dadonaite, B., Greaney, A.J., Eguia, R., Loes, A.N., Franko, N.M., Logue, J.,
Carreño, J.M., Abbad, A., Chu, H.Y., et al. (2022). Receptor binding domain (RBD)
antibodies contribute more to SARS-CoV-2 neutralization when target cells express high
levels of ACE2. bioRxiv, 2022.08.29.505713. https://doi.org/10.1101/2022.08.29.505713.

48. Greaney, A.J., Loes, A.N., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y., and
Bloom, J.D. (2021). Comprehensive mapping of mutations in the SARS-CoV-2 receptor-
binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host
Microbe *29*, 463-476.e6. https://doi.org/10.1016/j.chom.2021.02.003.

49. Greaney, A.J., Loes, A.N., Gentles, L.E., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu,
H.Y., and Bloom, J.D. (2021). Antibodies elicited by mRNA-1273 vaccination bind more
broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci.
Transl. Med. *13*, eabi9915. https://doi.org/10.1126/scitranslmed.abi9915.

50. Li, Z., Tomlinson, A.C., Wong, A.H., Zhou, D., Desforges, M., Talbot, P.J., Benlekbir, S.,
Rubinstein, J.L., and Rini, J.M. (2019). The human coronavirus HCoV-229E S-protein
structure and receptor binding. eLife *8*, e51230. https://doi.org/10.7554/eLife.51230.

51. Breslin, J.J., Mørk, I., Smith, M.K., Vogel, L.K., Hemmila, E.M., Bonavia, A., Talbot, P.J.,
Sjöström, H., Norén, O., and Holmes, K.V. (2003). Human Coronavirus 229E: Receptor
Binding Domain and Neutralization by Soluble Receptor at 37°C. J. Virol. *77*, 4435–4438.
https://doi.org/10.1128/JVI.77.7.4435-4438.2003.

52. Mou, H., Raj, V.S., Van Kuppeveld, F.J.M., Rottier, P.J.M., Haagmans, B.L., and Bosch,
B.J. (2013). The Receptor Binding Domain of the New Middle East Respiratory Syndrome
Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits
Neutralizing Antibodies. J. Virol. *87*, 9379–9383. https://doi.org/10.1128/JVI.01277-13.

53. Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X.,
et al. (2013). Structure of MERS-CoV spike receptor-binding domain complexed with human
receptor DPP4. Cell Res. *23*, 986–993. https://doi.org/10.1038/cr.2013.92.

54. Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., and Ben-Tal, N.
(2016). ConSurf 2016: an improved methodology to estimate and visualize evolutionary
conservation in macromolecules. Nucleic Acids Res. *44*, W344–W350.
https://doi.org/10.1093/nar/gkw408.

55. Kleanthous, H., Silverman, J.M., Makar, K.W., Yoon, I.-K., Jackson, N., and Vaughn, D.W.
(2021). Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.
Npj Vaccines *6*, 1–10. https://doi.org/10.1038/s41541-021-00393-6.

56. Piccoli, L., Park, Y.-J., Tortorici, M.A., Czudnochowski, N., Walls, A.C., Beltramello, M.,

Silacci-Fregni, C., Pinto, D., Rosen, L.E., Bowen, J.E., et al. (2020). Mapping Neutralizing
and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by
Structure-Guided High-Resolution Serology. Cell *183*, 1024-1042.e21.
https://doi.org/10.1016/j.cell.2020.09.037.

57. Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F.-W., Sahi, V.,
Figueroa, A., et al. (2020). Potent neutralizing antibodies against multiple epitopes on
SARS-CoV-2 spike. Nature *584*, 450–456. https://doi.org/10.1038/s41586-020-2571-7.

58. Poh, C.M., Carissimo, G., Wang, B., Amrun, S.N., Lee, C.Y.-P., Chee, R.S.-L., Fong, S.-W.,
Yeo, N.K.-W., Lee, W.-H., Torres-Ruesta, A., et al. (2020). Two linear epitopes on the
SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat.
Commun. *11*, 2806. https://doi.org/10.1038/s41467-020-16638-2.

59. Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J., Hauser,
B.M., Caradonna, T.M., Clayton, K.L., Nitido, A.D., et al. (2021). COVID-19-neutralizing
antibodies predict disease severity and survival. Cell *184*, 476-488.e11.
https://doi.org/10.1016/j.cell.2020.12.015.

60. Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et
al. (2022). Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals
neutralizing responses up to 16 months after infection. Nat. Microbiol. *7*, 423–433.
https://doi.org/10.1038/s41564-021-01051-2.

61. Stewart-Jones, G.B.E., Elbashir, S.M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein,
C.E., Choi, A., Whitener, B., et al. (2023). Domain-based mRNA vaccines encoding spike
protein N-terminal and receptor binding domains confer protection against SARS-CoV-2.
Sci. Transl. Med. *15*, eadf4100. https://doi.org/10.1126/scitranslmed.adf4100.

62. Hsieh, C.-L., Leist, S.R., Miller, E.H., Zhou, L., Powers, J.M., Tse, A.L., Wang, A., West, A.,
Zweigart, M.R., Schisler, J.C., et al. (2024). Prefusion-stabilized SARS-CoV-2 S2-only
antigen provides protection against SARS-CoV-2 challenge. Nat. Commun. *15*, 1553.
https://doi.org/10.1038/s41467-024-45404-x.

63. Halfmann, P.J., Frey, S.J., Loeffler, K., Kuroda, M., Maemura, T., Armbrust, T., Yang, J.E.,
Hou, Y.J., Baric, R., Wright, E.R., et al. (2022). Multivalent S2-based vaccines provide broad
protection against SARS-CoV-2 variants of concern and pangolin coronaviruses.
EBioMedicine *86*, 104341. https://doi.org/10.1016/j.ebiom.2022.104341.

64. Kong, R., Xu, K., Zhou, T., Acharya, P., Lemmin, T., Liu, K., Ozorowski, G., Soto, C., Taft,
J.D., Bailer, R.T., et al. (2016). Fusion peptide of HIV-1 as a site of vulnerability to
neutralizing antibody. Science *352*, 828–833. https://doi.org/10.1126/science.aae0474.

65. Wang, H., Cheng, C., Dal Santo, J.L., Shen, C.-H., Bylund, T., Henry, A.R., Howe, C.A.,
Hwang, J., Morano, N.C., Morris, D.J., et al. (2024). Potent and broad HIV-1 neutralization
in fusion peptide-primed SHIV-infected macaques. Cell *187*, 7214-7231.e23.
https://doi.org/10.1016/j.cell.2024.10.003.

66. WHO chief declares end to COVID-19 as a global health emergency | UN News (2023).
https://news.un.org/en/story/2023/05/1136367.

67. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-
19 pandemic https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-
of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-
coronavirus-disease-(covid-19)-pandemic.

68. Roederer, A.L., Cao, Y., St. Denis, K., Sheehan, M.L., Li, C.J., Lam, E.C., Gregory, D.J.,
Poznansky, M.C., Iafrate, A.J., Canaday, D.H., et al. (2024). Ongoing evolution of SARS-
CoV-2 drives escape from mRNA vaccine-induced humoral immunity. Cell Rep. Med. *5*,
101850. https://doi.org/10.1016/j.xcrm.2024.101850.

69. Dacon, C., Tucker, C., Peng, L., Lee, C.-C.D., Lin, T.-H., Yuan, M., Cong, Y., Wang, L.,
Purser, L., Williams, J.K., et al. (2022). Broadly neutralizing antibodies target the
coronavirus fusion peptide. Science *377*, 728–735.
https://doi.org/10.1126/science.abq3773.

70. Siebring-van Olst, E., Vermeulen, C., de Menezes, R.X., Howell, M., Smit, E.F., and van
Beusechem, V.W. (2013). Affordable luciferase reporter assay for cell-based high-
throughput screening. J. Biomol. Screen. *18*, 453–461.
https://doi.org/10.1177/1087057112465184.

Figure 1: Broad neutralizers have extensive breadth across related Beta coronaviruses.

(A) A cohort of 382 donor samples was divided into four groups based on neutralization potency (average of n = 2 technical replicates) against SARS-CoV-2 WT and the BA.1 and BA.5 variants, with a detection limit of pNT_{50} = 8748. Samples with pNT_{50} > 2000 against WT and > 1500 against both BA.1 and BA.5 were classified as *Broad-Potent*. Samples with at least one but not all pNT_{50} values exceeding these thresholds were classified as *Narrow-Potent*. Samples with pNT_{50} < 300 against WT and < 100 against BA.1 and BA.5 were classified as *Weak*, and all remaining samples were classified as *Moderate*. Because data did not pass normality tests (Shapiro-Wilk p < 0.05), non-parametric analyses were used. pNT_{50} values were compared using the Kruskal-Wallis test followed by Dunn's multiple comparisons test (* = P<0.0332, ** = P<0.0021, ***= P<0.0002, ****= P<0.0001).

(B) A subset of donor samples from each group were subject to our high throughput neutralization assay against SARS-CoV-2, variants, Beta Coronaviruses, and other distantly related coronaviruses for neutralizing activity (average of n = 2 technical replicates).

(C) A subset of *broad-potent* samples was further tested against Beta Coronaviruses (excluding MERS) with a much higher threshold for neutralizing activity (average of n = 2 technical replicates).

(D) Sera from (C) were subdivided into *broad-extra-potent* and *broad-potent* groups based on average neutralizing activity across the tested viruses using the cutoff pNT_{50} = 5000. Because the data were approximately normally distributed (Shapiro-Wilk p > 0.05), neutralization titers were compared between the groups using an unpaired two-tailed t-test with Welch's correction for unequal variances.

Figure 2: Broad-extra-potent sera have the highest levels of RBD, FP and SH antibodies.

(A) Conservation of the amino acids within the spike protein generated using consurf[55] from (PDB 6XR8 https://doi.org/10.2210/pdb6xr8/pdb). The sequences fed into the algorithm include 59 coronavirus spike sequences representing all four clades. RBD = Receptor Binding Domain, NTD = N-Terminal Domain, FP = Fusion Peptide, SH = Stem Helix.

(B-E) Results from ELISA assessing the antibody endpoint titers of plasma from 21 *broad-extra-potent*, 16 *broad-potent*, 11 *narrow-potent*, 17 *moderate* and 9 *weak* donors. Antibody endpoint titers (average of n = 2 technical replicates) were assessed against an S2P Stabilized spike (B), Receptor Binding Domain (C), Fusion Peptide (D), or Stem Helix Peptide (E). Antibody endpoint titer represents the maximum interpolated dilution that can still bind the antigen. The endpoint titers were evaluated at a top dilution of 100-fold with seven additional 3-fold serial dilutions. The wells incubated with no plasma incubation were used as controls, and cut-off values (used for interpolation) were defined as 2.1X the OD450 of the controls. Representative data from two independent experiments is shown. Because data did not pass normality tests (Shapiro-Wilk p < 0.05), non-parametric analyses were used. Endpoint titer values were compared using the Kruskal-Wallis test followed by Dunn's multiple comparisons test (* = P<0.0332, ** = P<0.0021, ***= P<0.0002, ****= P<0.0001).

(F) *Broad-extra-potent* data from Figure 2B-D were further divided into two groups based on COVID history. Samples from COVID-naïve donors were outlined in gray, and those from COVID-experienced donors were outlined in black. Endpoint titers were compared between groups using an unpaired two-tailed t-test with Welch's correction for unequal variances. ** = P<0.0021.

Figure 3: RBD and fusion peptide specific antibody titers correlate with neutralizing activity.
(A-D, left) Unit/mL (U/mL) of antigen specific antibody was assessed for a cohort of broad and potent neutralizers (average of n = 2 technical replicates). All U/mL were calculated using an antigen specific ELISA and were defined as the equivalent reactivity to 1 μg/mL binding of the following antibodies: RBD182 for Spike (A) and RBD (B), 76E1 for FP (C), S2P6 for SH (D). A negative control antibody (2A10) at the same concentration as the serum dilution was included to determine cutoff values to define background serum binding. Data below the cutoff were excluded from subsequent correlation analyses.
(A-D, right) Log-log regression analyses were performed on neutralization versus anti-Spike IgG (A), anti-RBD IgG (B), anti-FP IgG (C), and anti-SH IgG (D). Pearson correlations were performed and R^2 and p values are indicated.

Figure 4: Fusion peptide antibodies contribute to neutralization breadth.

(A) Schematic detailing our antigen depletion protocol. Briefly, his-tag or maleimide binding magnetic beads are pre-coupled to the antigen/peptide and mixed with serum. After an incubation the magnetic beads are pulled away using a magnet and serum is collected for downstream assays. Mock depletion is done by mixing serum and beads with no antigen (Created in BioRender).

(B-C) Serum samples with high neutralizing activity were subject to RBD based depletion using his-tagged beads or mock depletion using beads with no RBD bound. Mock and depleted serum was tested for neutralizing activity (average of n = 2 technical replicates) against SARS-CoV-2 (C) and SARS-CoV (D).

(D-E) Serum samples with remaining neutralizing activity against both SARS-CoV-2 and SARS-CoV from (B-C) were subject to further depletion with the fusion peptide and tested for remaining neutralizing activity (average of n = 2 technical replicates) to SARS-CoV-2 (D) and SARS-CoV (E) after double depletion.

Figure 5: Fusion peptide antibodies develop in response to natural infection.

(A) Anti-Fusion Peptide ELISA for a cohort of COVID-experienced pre-vaccination timepoints split into non-hospitalized and hospitalized (average of n = 2 technical replicates). Limit of detection line is defined as the background binding of a negative control antibody to the FP for that experiment. Because the data did not follow a normal distribution (Shapiro-Wilk p < 0.001), differences between these groups were analyzed using the Mann-Whitney U test (two-tailed). * = P<0.0332.

(B) Anti-Fusion Peptide ELISA (average of n = 2 technical replicates) for pre-vaccination serum samples for donors who were naïve or who had been infected with COVID. A Mann Whitney Two tailed T-test was performed to assess significance. ****= P<0.0001.

(C) Anti-Fusion Peptide ELISA (average of n = 2 technical replicates) for post-vaccination serum samples for donors who were naïve after 2-6 vaccines or who were COVID-experienced at the timepoint and had received between 2-6 vaccines. A Mann Whitney Two tailed T-test was performed to assess significance. ***= P<0.0002.

(D) Fusion peptide ELISA (average of n = 2 technical replicates) was performed for a cohort of COVID naïve donors at various stages of vaccination. No significance was seen between groups in the development of FP specific antibodies. Limit of detection line is defined as the background binding of a negative control antibody to the FP for that experiment.

(E) Anti-Fusion Peptide ELISA (average of n = 2 technical replicates) for longitudinal timepoints of donors who had a breakthrough infection between 2nd vaccine and bivalent. Pre-Breakthrough (Pre-BT) indicates the time point closest to breakthrough infection (BT) timepoint. A Kruskal Wallis one-way ANOVA was performed with Dunn's correction for multiple comparisons (* = P<0.0332, ** = P<0.0021, ***= P<0.0002, ****= P<0.0001).

For A-E U/mL is defined as the reactivity seen by 1 µg/mL of 76E1 antibody[43]. Cutoffs were determined by binding of a negative control antibody (2A10).

A

B

C

D

Antibody	Virus	IC$_{50}$ Literature	IC$_{50}$ Calculated
76E1	MERS	3.825 µg/mL	28.8 µg/mL
S2P6	MERS	17 µg/mL	5.23 µg/mL
COV44-62	MERS	25 µg/mL	19.77 µg/mL
COV44-62	229E	2.11 µg/mL	0.594 µg/mL
76E1	229E	1.16 µg/mL	2.31 µg/mL

E

F

Figure S1 (related to **Fig. 1**): **Individual neutralization values for donor cohort and development and validation of MERS and 229E neutralization assays.**

(A) Neutralization Assay results (average of n = 2 technical replicates) against SARS-CoV-2 WT and BA.1, BA.5 variants for a cohort of 382 donor samples.

(B-C) Adaptation of our high throughput neutralization assay to evaluate MERS (B) and 229E (C) neutralization. We transduced 293T cells to express either hDPP4 (B) or hANPEP (C) and confirmed cell-surface expression by flow cytometry (Left). These cell lines were tested for transduction by MERS (B) or 229E (C) pseudoviruses, respectively (Middle). Finally, we performed neutralization assays with known neutralizing antibodies COV44-62, 76E1, and S2P6, and 2A10 as a negative control to evaluate these cell lines and pseudoviruses (Right). Data represented as mean +/- SD.

(D) Table comparing the IC_{50} values for antibodies in the literature relative to IC_{50} values we calculated.

(E) Average neutralizing activity of 382 serum samples from donors who were either COVID-naïve or previously infected. Because the data did not follow a normal distribution (Shapiro-Wilk p < 0.0001), differences between COVID-naïve and COVID-experienced groups were analyzed using the Mann-Whitney U test. ****= P<0.0001.

(F) Samples from naïve donors (left) or COVID-experienced donors (right) were divided into five groups based on neutralization potency, as defined in Figure 1A. Pie charts represent the proportion of each group.

Figure S2 (related to **Fig. 2**): **Broad extra potent samples from naïve donor have higher levels of FP antibodies.**

(A-D) Data from Figure 2B-E were further divided into two groups based on COVID history. Samples from COVID-naïve donors were outlined in gray, and those from COVID-experienced donors were outlined in black. Endpoint titers were compared between each COVID-naïve and COVID-experienced group using an unpaired two-tailed t-test with Welch's correction for unequal variances. ** = P<0.0021.

Figure S3 (related to **Fig. 3**): **Repeated vaccination does not correlate with antigen specific antibodies, nor does it increase neutralization against alpha coronaviruses or MERS.**

(A-D) ELISA (average of n = 2 technical replicates) results for anti-SARS-CoV-2 Spike (A), anti-RBD (B), anti-Fusion Peptide (C), and anti-Stem Helix (D) antibodies. One U/mL is defined as the equivalent reactivity seen by 1 µg/mL RBDCOV182 antibody or 1 µg/mL S2P6 for SH or 1 µg/mL 76E1 for FP. Each line corresponds to a single donor over time.

(E-G) Neutralizing titer (average of n = 2 technical replicates) against NL63 (E), 229E (F), or MERS (G) was assessed for longitudinal timepoints. Each line corresponds to a single donor over time.

Figure S4 (related to **Fig, 4**): **Antigen depletions effectively remove antigen specific antibodies.**
(A) Selectivity of RBD depletion. Serum samples were subject to Mock or RBD depletion and then tested by ELISA (average of n = 2 technical replicates) for binding to either the Fusion Peptide (left) or Stem Helix (right). Two representative samples are shown for each depletion for samples that had strong binding to either the FP or the SH.
(B) Selectivity of Fusion Peptide or Stem Helix Depletion. Serum samples were subject to depletion against either the FP (left) or the SH (right) and then tested for binding to RBD by an ELISA (average of n = 2 technical duplicates). Two representative samples are shown for each depletion.
(C-D) Depletion ELISA detailing the effect of FP (C) or SH (D) depletion on 6-8 broadly neutralizing samples. Samples with high FP or SH binding were chosen for depletion with those antigens. U/mL is calculated with 1 U/mL defined as the equivalent reactivity seen by 1 μg/mL, 76E1[43] for FP and S2P6[41] for SH. Cutoffs were defined by a negative control antibody (2A10).
(E-F) Serum samples were subject to either fusion peptide or stem helix depletion to remove peptide specific antibodies and then tested for neutralizing activity (average of n = 2 technical replicates) to either SARS-CoV-2 (E) or SARS-CoV (F). Mock samples were combined with beads only for mock depletion.
(G) Depletion ELISA (average of n = 2 technical replicates) detailing the effect of RBD depletion on 17 broadly neutralizing samples. Samples with high FP or SH binding were chosen for depletion with those antigens. U/mL is calculated with 1 U/mL defined as the equivalent reactivity seen by 1 μg/mL RBDCOV182 (isolated in house) antibody for RBD. Cutoffs were defined by a negative control antibody (2A10).
(H) RBD Depleted donors with remaining neutralizing activity were subject to fusion peptide depletion and an ELISA (average of n = 2 technical replicates) was done to confirmed depletion. Cutoffs were defined by a negative control antibody (2A10).

Figure S5 (related to **Fig. 5**): **Age, race, and biological sex did not correlate with FP antibody development.**
(A-C) Fusion peptide U/mL ELISA (average of n = 2 technical replicates) for COVID-experienced donors separated by age (A), race (B), biological sex (C). Age, race and biological sex were not correlated with FP-specific antibodies.
For A-C U/mL is defined as the reactivity seen by 1 µg/mL of 76E1[43] antibody. Cutoffs were determined by binding of a negative control antibody (2A10).

Cohort	Statistics
Total (n)	382
Broad Extra Potent	16
Age (y) (median, range)	70 (57-77)
Biological Sex (% Female)	7/16 (44%)
COVID History (% Experienced)	11/16 (69%)
Broad Potent	31
Age (y) (median, range)	73 (57-93)
Biological Sex (% Female)	20/31 (65%)
COVID History (% Experienced)	21/31 (68%)
Narrow Potent	49
Age (y) (median, range)	77 (40-97)
Biological Sex (% Female)	32/49 (65%)
COVID History (% Experienced)	42/49 (86%)
Moderate	153
Age (y) (median, range)	76 (33-100)
Biological Sex (% Female)	62/153 (41%)
COVID History (% Experienced)	103/153 (67%)
Weak	133
Age (y) (median, range)	73 (49-100)
Biological Sex (% Female)	23/133 (17%)
COVID History (% Experienced)	73/133 (55%)

Table S1 (related to **Fig 1A**): **Cohort Descriptions for Figure 1A**
Descriptions of the various groups for Figure 1A and Supplemental Figure 1A with age and sex noted.

Timing of Sampling	Total	Weak (n=133)	Moderate (n=153)	Narrow Potent (n=49)	Broad Potent (n=27)	Broad Extra Potent (n=20)
Pre-boost	16	11/16 (69%)	5/16 (31%)	0/16 (0%)	0/16 (0%)	0/16 (0%)
2 Weeks After First Boost	39	3/39 (8%)	19/39 (49%)	9/39 (23%)	5/39 (13%)	3/39 (8%)
3 Months After First Boost	27	16/27 (59%)	10/27 (37%)	0/27 (0%)	1/27 (4%)	0/27 (0%)
6 Months After First Boost	99	47/99 (47%)	40/99 (40%)	7/99 (7%)	3/99 (3%)	2/99 (2%)
12 Months After First Boost	57	40/57 (70%)	16/57 (28%)	0/57 (0%)	1/57 (2%)	0/57 (0%)
2 Weeks After Second Boost	70	1/70 (1%)	31/70 (44%)	18/70 (26%)	16/70 (23%)	4/70 (6%)
3 Months After Second Boost	67	15/67 (22%)	32/67 (48%)	15/67 (22%)	1/67 (1%)	4/67 (6%)
2 Weeks After Third Boost	5	0/5 (0%)	0/5 (0%)	0/5 (0%)	0/5 (0%)	5/5 (100%)
3 Months After Third Boost	2	0/2 (0%)	0/2 (0%)	0/2 (0%)	0/2 (0%)	2/2 (100%)

Table S2 (related to **Fig 1A**): **Collection Time Points of Samples Analyzed in Figure 1A**
Number of samples collected at each time point. All donors received one vaccination followed by at least one booster dose. Sera were collected either before the booster (pre-boost) or at 2 weeks, 3 months, 6 months, or 12 months after vaccination.

	COVID Naive	COVID Experienced
Total (n)	132	250
Age (y) (median, range)	73 (33-100)	74 (40-100)
Biological Sex (% Female)	31/132 (23%)	113/250 (45%)
Weak	60/127 (45%)	73/250 (29%)
Moderate	50/127 (38%)	103/250 (41%)
Narrow Potent	7/127 (5%)	41/250 (17%)
Broad Potent	10/127 (8%)	21/250 (8%)
Broad Extra Potent	5/127 (4%)	11/250 (4%)

Table S3 (related to **Fig S1E**): **Comparison of Samples from COVID-Naïve or Experienced Donors Analyzed in Supplemental Figure 1E**
Descriptions of samples from donors who were either COVID-naïve or previously infected with age and sex noted. Proportion of sample numbers in each groups were also analyzed.

Donor	Age	Biological Sex	Vaccination Status	Infection History
1	81-85	Male	4XWT, 1XBivalent	Infection Prior to 1st Vax
2	66-70	Female	4XWT, 1XBivalent	Naive
3	55-60	Male	4XWT, 1XBivalent	Infection Prior to 1st Vax
4	61-65	Male	4XWT, 1XBivalent	Naive
5	61-65	Female	4XWT, 1XBivalent	Infection After 4th Vax
6	66-70	Female	4XWT, 1XBivalent	Infection Prior to 1st Vax
7	86-90	Female	4XWT, 1XBivalent	Naive
8	76-70	Male	4XWT, 1XBivalent	Infection Prior to 1st Vax Infection after 4th Vax

Table S4 (related to **Fig 3, 4**): **Demographics of longitudinal donor cohort.**
Table describing individual timepoints from 8 of the broadest neutralizing donors spanning 3-5 timepoints including those 2-4 weeks after vaccination as well as timepoints that were distant (Post) from the nearest vaccination (3-6 months post) from a cohort of Nursing Home Samples.

Cohort	Statistics
Total (n)	255
Demographics All Cohorts	
Age (y) (median, range)	69 (25-96)
Biological Sex (% Female)	93/255 (36%)
COVID+ Pre-Vaccination Total (n)	74
Age (y) (median, range)	63 (25-96)
Biological Sex (% Female)	33/94 (35.1%)
COVID Naïve Pre-Vaccine Total (n)	14
Age (y) (median, range)	70 (60-88)
Biological Sex (% Female)	3/14 (21%)
COVID Experienced Pre-Vaccine Total (n)	71
Age (y) (median, range)	55 (25-96)
Biological Sex (% Female)	29/71 (41%)
COVID Naïve Post-Vaccine (5C) Total (n)	72
Age (y) (median, range)	73 (49-89)
Biological Sex (% Female)	35/72 (49%)
COVID Experienced Post-Vaccine (5C) Total (n)	52
Age (y) (median, range)	70 (37-88)
Biological Sex (% Female)	13/52 (25%)
COVID Naïve Longitudinal (5D) Total (n)	30
Age (y) (median, range)	73 (49-88)
Biological Sex (% Female)	10/30 (33%)
Longitudinal BT Cohort (5E) Total (n)	7
Age (y) (median, range)	73 (65-88)
Biological Sex (% Female)	2/7 (29%)

Table S5 (related to **Fig 5**): **Cohort Descriptions for Figure 5**
Descriptions of the various cohorts for Figure 5 and Supplemental Figure 5 with age and sex noted.